Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Tolerability of Tumor Treating Fields (TTFields) Combined With Chemoradiation in Newly Diagnosed Glioblastoma (Unity)

Trial Profile

Safety and Tolerability of Tumor Treating Fields (TTFields) Combined With Chemoradiation in Newly Diagnosed Glioblastoma (Unity)

Status: Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Temozolomide (Primary)
  • Indications Glioblastoma; Gliosarcoma
  • Focus Adverse reactions
  • Acronyms Unity
  • Most Recent Events

    • 26 Nov 2019 Planned initiation date changed from 1 Nov 2019 to 2 Dec 2019.
    • 25 Sep 2019 Planned End Date changed from 1 Apr 2025 to 1 Nov 2025.
    • 25 Sep 2019 Planned primary completion date changed from 1 Apr 2023 to 1 Nov 2023.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top